ATE489972T1 - Einschlusskomplexe aus butylphthalid und cyclodextrin derivaten und verfahren zu deren herstellung - Google Patents

Einschlusskomplexe aus butylphthalid und cyclodextrin derivaten und verfahren zu deren herstellung

Info

Publication number
ATE489972T1
ATE489972T1 AT02760059T AT02760059T ATE489972T1 AT E489972 T1 ATE489972 T1 AT E489972T1 AT 02760059 T AT02760059 T AT 02760059T AT 02760059 T AT02760059 T AT 02760059T AT E489972 T1 ATE489972 T1 AT E489972T1
Authority
AT
Austria
Prior art keywords
butylphthalide
cyclodextrin
cyclodextrin derivatives
inclusion complexes
production
Prior art date
Application number
AT02760059T
Other languages
English (en)
Inventor
Zhan-Qi Niu
Kai Zhao
Wen-Juan Liu
Gui-Rong Zhou
Chao Liu
Rong-Duan Wang
Hong-Zhong Yuan
Wen-Min Guo
Sui-Chao Yan
Min Bai
Original Assignee
Shijiazhuang Pharma Group Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31892708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE489972(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shijiazhuang Pharma Group Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd filed Critical Shijiazhuang Pharma Group Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Application granted granted Critical
Publication of ATE489972T1 publication Critical patent/ATE489972T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT02760059T 2002-08-21 2002-08-21 Einschlusskomplexe aus butylphthalid und cyclodextrin derivaten und verfahren zu deren herstellung ATE489972T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2002/000579 WO2004018444A1 (en) 2002-08-21 2002-08-21 Clathrates of butylphtualide with cyclodextrin or its derivatives, a process for their preparations and the use there of

Publications (1)

Publication Number Publication Date
ATE489972T1 true ATE489972T1 (de) 2010-12-15

Family

ID=31892708

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02760059T ATE489972T1 (de) 2002-08-21 2002-08-21 Einschlusskomplexe aus butylphthalid und cyclodextrin derivaten und verfahren zu deren herstellung

Country Status (12)

Country Link
US (2) US20060166931A1 (de)
EP (1) EP1535916B1 (de)
JP (1) JP4378755B2 (de)
AT (1) ATE489972T1 (de)
AU (1) AU2002327307B8 (de)
BR (1) BR0215848A (de)
CA (1) CA2494157C (de)
DE (1) DE60238510D1 (de)
DK (1) DK1535916T3 (de)
ES (1) ES2355133T3 (de)
NO (1) NO20050629L (de)
WO (1) WO2004018444A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1605336A (zh) * 2003-10-10 2005-04-13 中国医学科学院药物研究所 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用
CN1257711C (zh) * 2003-12-05 2006-05-31 石药集团中奇制药技术（石家庄）有限公司 丁苯酞软胶囊及其制备工艺
US8552058B2 (en) 2004-06-18 2013-10-08 CSPC Zhongqi Pharmaceutical Technology (Shijazhuang) Co., Ltd. Application of L-n-butylphthalide in preventing and treating dementia
CN100361656C (zh) * 2004-08-27 2008-01-16 石药集团中奇制药技术（石家庄）有限公司 丁苯酞自乳化释药体系及其制备方法和应用
CN100367951C (zh) 2005-12-16 2008-02-13 石药集团恩必普药业有限公司 丁苯酞静脉乳剂及其应用
CN101342152B (zh) * 2007-07-10 2010-10-13 石药集团中奇制药技术（石家庄）有限公司 丁苯酞片及其制备方法
CN107970208B (zh) * 2012-06-27 2021-01-19 石药集团中奇制药技术（石家庄）有限公司 一种丁苯酞注射液及其制备方法
CN103784424B (zh) * 2012-10-30 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 一种丁苯酞经皮贴剂及其制备方法
CN105616375B (zh) * 2013-03-06 2018-08-28 贵州贵安新区协生元医药科技有限公司 消旋2-(α-羟基戊基)苯甲酸盐片及其制备方法
CN105380908B (zh) * 2015-12-09 2018-08-10 河北大学 一种丁苯酞药物复合物及其制备方法和缓释制剂
CN108553412B (zh) * 2018-05-14 2019-10-29 田普森 一种含丁苯酞与增溶剂药物组合物
CN110548004B (zh) * 2018-05-30 2023-05-16 成都施贝康生物医药科技有限公司 一种稳定的丁苯酞大容量注射液及其制备方法
CN111743892A (zh) * 2019-03-26 2020-10-09 石家庄以岭药业股份有限公司 丁苯酞衍生物在制备治疗心梗或其相关疾病药物中的应用
CN112386571B (zh) * 2020-12-04 2024-01-26 成都施贝康生物医药科技有限公司 一种稳定的丁苯酞氯化钠注射液、其制备方法及用途
CN114685410B (zh) * 2020-12-26 2023-09-29 四川汇宇制药股份有限公司 一种丁苯酞的制备方法
CN112999175B (zh) * 2021-04-26 2021-08-03 奥信阳光(北京)药业科技有限公司 一种丁苯酞口服冻干粉及其制备方法和用途
CN114315585B (zh) 2022-03-04 2022-05-13 中国医学科学院药用植物研究所 一种羟戊苯甲酸双酯化合物及其制备方法和制药应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
CN1048158C (zh) 1993-09-09 2000-01-12 中国医学科学院药物研究所 芹菜甲素在制备预防和治疗哺乳动物或人类脑缺血引起的疾病的药中的应用
CN1086942C (zh) * 1998-12-18 2002-07-03 中国医学科学院药物研究所 丁基苯酞在制备抗血栓形成及抗血小板聚集药物中的应用
CN1136209C (zh) * 1999-07-05 2004-01-28 中国医学科学院药物研究所 制备光学活性3-正丁苯酞的方法

Also Published As

Publication number Publication date
JP2006500367A (ja) 2006-01-05
HK1074200A1 (en) 2005-11-04
US7678776B2 (en) 2010-03-16
AU2002327307A1 (en) 2004-03-11
EP1535916A4 (de) 2006-09-20
DK1535916T3 (da) 2011-03-14
NO20050629L (no) 2005-03-17
US20060166931A1 (en) 2006-07-27
EP1535916B1 (de) 2010-12-01
AU2002327307B8 (en) 2009-02-26
CA2494157C (en) 2010-10-12
BR0215848A (pt) 2005-06-21
AU2002327307B2 (en) 2009-02-12
US20080318898A1 (en) 2008-12-25
DE60238510D1 (de) 2011-01-13
JP4378755B2 (ja) 2009-12-09
WO2004018444A1 (en) 2004-03-04
EP1535916A1 (de) 2005-06-01
CA2494157A1 (en) 2004-03-04
ES2355133T3 (es) 2011-03-23

Similar Documents

Publication Publication Date Title
DE60238510D1 (de) Einschlusskomplexe aus butylphthalid und cyclodextrin derivaten und verfahren zu deren herstellung
AU772204B2 (en) Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method
ATE493992T1 (de) Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE163008T1 (de) Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
ATE243686T1 (de) Mit zuckerresten substituierte 1,4-benzothiazepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE477265T1 (de) Neue thiophenglycosidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
KR960700074A (ko) 고용해성다성분봉입체착화합물(Highy soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin)
ATE492554T1 (de) Neue mit benzylresten substituierte 1,4- benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2008146016A3 (en) Cyclodextrins for administering fatty acids in tablets
HRP20131150T1 (hr) Pimobendan za uporabu u lijeäśenju hipertrofiäśne kardiomiopatije kod maäśaka
WO2003096975A3 (en) Pharmaceutical compositions and methods of using c-21 modified epothilone derivatives
EE200200057A (et) Kasvutegurit IL-5 pärssiv asauratsiilderivaat, selle saamine ja kasutamine ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
KR937000160A (ko) 사이클로덱스트린과 니메설리드의 포접 화합물
NO20040601L (no) Fremgangsmate for fremstilling av piroxicam: beta-cyklodekstrin-inklusjonsforbindelser
ATE269352T1 (de) 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung
ATE308537T1 (de) Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JP2018526420A5 (de)
ATE298567T1 (de) Pharmazeutische zusammensetzung enthaltend ibuprofen und ein verfahren zur deren herstellung
Pourmokhtar et al. Enhanced stability of sulfamethoxazole and trimethoprim against oxidation using hydroxypropyl-β-cyclodextrin
ATE493134T1 (de) Gefriergetrocknetes präparat mit methylcobalamin und verfahren zu seiner herstellung
CN114569742B (zh) 一种组合物及其制备方法和应用
ATE301452T1 (de) Verfahren zur herstellung einer flüssigen dosierungseinheit und kit
YU81101A (sh) Polimorfni oblici kristalnog citrata azabiciklo (2,2,2) oktan-3-amina i njihovih farmaceutskih kompozicija
EP1109806B8 (de) Komplexe von paroxetin mit cyclodextrin oder cyclodextrin derivaten
El-Saleh et al. The use of cyclodextrins in preparing a pediatric oral liquid dosage form of loratadine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1535916

Country of ref document: EP